Fluence Leads Global Research Initiative to Study Impact of Light Quality on Plant Development, Yield and Crop Quality
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, has expanded its global photobiology research program, which encompasses studies on multiple vine crops, leafy greens and medical cannabis in the United States, Canada, Germany, Belgium and the Netherlands.
Tapping into a global network of trusted research institutions
Fluence leverages a network of leading research institutions and partners for its program, including Wageningen University & Research (WUR) for tomatoes; Proefstation voor de Groenteteelt (Proefstation) to study cucumbers; Harrow Research and Development Centre for peppers; The Technical University of Munich's Greenhouse Lab Centre for lettuce; Wageningen Plant Research’s Greenhouse Horticulture business unit and Compassionate Cultivation for medical cannabis.
The latest studies utilized Fluence’s VYPR Series top light and expanded PhysioSpec™ spectra offering —which features four spectra and market-leading efficacies up to 3.8 µmol/J—in a randomized block design with triple replicates during a winter growing season. A leader in global horticultural research, WUR explored the impact of each spectrum on Merlice and Brioso tomato cultivars.
“Traditionally, tomato plants are grown under high-pressure sodium lights, where only one spectrum is available to growers,” said Ep Heuvelink, associate professor of horticulture and product physiology at WUR. “Given the efficacy of Fluence's LED solutions and the company's spectra options, it’s critical to understand how various tomato cultivars perform under LEDs and diversified spectra.”
Featuring a 1.3-hectare greenhouse with 38 independent compartments, Proefstation’s facility brings more than 50 years of experience in research on the cultivation of greenhouse and field vegetables.
“Light spectra have an important impact on plant and fruit quality, and we’ve found that LEDs provide a more optimal, precise spectrum than HPS,” said Jonas De Win, lead cucumber researcher at Proefstation. “This research is critical for our growers who frequently ask which spectra is best for their greenhouse and crop variety. Our goal is to act as the bridge between cucumber growers and the latest scientific research, enabling cultivators to enhance their environments and ultimately become more profitable.”
Crop-based research results inform unique lighting strategies
“LED lighting is a proven, viable option for global crop growers,” said David Cohen, CEO of Fluence. “Our exploration of the impact of light quality on plant development is driving a deeper conversation about efficacy, yield and quality between growers and their partners. Our commitment to leading cross-geography, multi-crop research will help guide growers in building a supplemental lighting strategy tailored to their unique business goals.”
Fluence will distribute research results throughout the year, uncovering how the optimal lighting strategy varies by crop, species and environment. Results from Fluence’s cucumber trial with Proefstation will be previewed on July 15, 2020 on a webinar hosted by Leo Lansbergen, Fluence’s horticulture service specialist and expert in cucumber cultivation.
“There is no one-size-fits-all approach to determining your lighting strategy,” said David Hawley, Ph.D., Fluence’s senior scientist. “Exploring how to manipulate LED technology presents a world of opportunity for us as scientists, but ultimately benefits growers looking to customize their cultivation environments. Insights derived from each study will help growers understand how various spectra impact harvests and plant quality, including factors ranging from nutrition and flavor to shelf life.”
For more information about Fluence and its ongoing research initiatives, visit www.fluence.science.
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science.
Link to high resolution pictures: www.fluence.science/press-links
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005470/en/
Contact information
Media Contact:
For North America,
Emma Chase
emma@redfancommunications.com
Phone: 512-917-4319
For EMEA,
Silvia Nagyova
s.nagyova@osram.com
Phone: +49 (89) 6213-3939
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
